Bunkerhill Abdominal Aortic Quantification (AAQ) vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Bunkerhill Abdominal Aortic Quantification (AAQ)

by BunkerHill Health

EchoNext

by Pathway Labs

AI Verdict

Both Bunkerhill Abdominal Aortic Quantification (AAQ) and EchoNext are FDA-cleared AI tools in cardiology, but they address different diagnostic needs. Bunkerhill AAQ focuses on automating the quantification of abdominal aortic diameter from CT scans for aneurysm detection and follow-up, while EchoNext analyzes standard ECGs to detect hidden structural heart diseases like heart failure and valve disease. Therefore, the choice between them depends on whether the primary need is aortic aneurysm screening via CT or broad structural heart disease detection via ECG.

Choose Bunkerhill Abdominal Aortic Quantification (AAQ) if…

Choose Bunkerhill Abdominal Aortic Quantification (AAQ) if your institution performs a high volume of CT scans and aims to proactively screen for abdominal aortic aneurysms and manage follow-up care. This tool excels at automating aortic diameter quantification on both contrast and non-contrast CTs, integrating seamlessly with EHRs and the Carebricks platform to streamline patient follow-up workflows and ensure guideline-based surveillance.

View Bunkerhill Abdominal Aortic Quantification (AAQ) →

Choose EchoNext if…

Choose EchoNext if your practice seeks an accessible, non-invasive method to screen a broad patient population for hidden structural heart disease using standard ECGs. This AI tool is particularly well-suited for early detection of conditions like heart failure, valve disease, and pulmonary hypertension, offering a cost-effective and scalable front-line screening solution, especially in settings with limited access to echocardiography.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Bunkerhill Abdominal Aortic Quantification (AAQ)	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Cloud-based (utilizes AWS for cloud infrastructure)	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Yes AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Bunkerhill Abdominal Aortic Quantification (AAQ)

Bunkerhill AAQ integrates with the Carebricks platform, which is designed to automate follow-up workflows and integrate seamlessly with EHRs, suggesting a focus on streamlining existing clinical processes. EchoNext is available through the OpenEvidence platform, but its description focuses more on diagnostic accuracy rather than workflow automation or EHR integration.

Clinical Value

EchoNext

EchoNext has demonstrated high diagnostic accuracy in detecting structural heart disease from ECGs, even outperforming cardiologists in studies. It has also been credited with identifying severe, undiagnosed heart failure that led to a heart transplant. While Bunkerhill AAQ automates aortic diameter quantification and enables early aneurysm detection, its clinical impact is focused on a more specific condition.

Pricing & Value

EchoNext

EchoNext provides transparent tiered pricing starting at $600/month, allowing potential customers to understand the cost structure upfront. Bunkerhill AAQ requires contacting them for custom pricing, which offers less transparency.

Enterprise Readiness

Bunkerhill Abdominal Aortic Quantification (AAQ)

Bunkerhill AAQ is part of the broader Carebricks platform, which is designed for system-wide deployment and has been implemented at large health systems like UTMB Health to support a wide range of AI workflows. This indicates a robust infrastructure for enterprise-scale integration and continuous AI execution. EchoNext is available through OpenEvidence, a platform used by many physicians, but its enterprise deployment capabilities are not as explicitly detailed as Bunkerhill's Carebricks.

Innovation

Bunkerhill Abdominal Aortic Quantification (AAQ)

Bunkerhill AAQ leverages a generative AI platform (Carebricks) for clinical reasoning and action, enabling the automation of appropriate next steps and actions within clinical workflows, including opportunistic screening and guideline-based surveillance. This goes beyond simple detection to actively integrate AI into care pathways. EchoNext's innovation lies in its ability to detect hidden structural heart disease from standard ECGs, a significant diagnostic breakthrough, but its description focuses primarily on detection rather than broader workflow automation.

Support & Docs

Tie

Both companies imply support through their 'contact us' or 'book a demo' options. Bunkerhill Health also provides a trust center with SOC 2 Type II Report, Pen Test Report, and ISO 27001:2022 Certificate, indicating a commitment to security and compliance documentation. However, specific details about ongoing customer support, training, or extensive documentation for either tool are not explicitly provided in the given information or search results.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Bunkerhill Abdominal Aortic Quantification (AAQ)	EchoNext
Tool Name	Bunkerhill Abdominal Aortic Quantification (AAQ)	EchoNext
Company	BunkerHill Health	Pathway Labs
Description	The first FDA-cleared AI to automate abdominal aortic diameter quantification on contrast and non-contrast CT scans, enabling early aneurysm detection and streamlined follow-up within the Carebricks platform.	An FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Primary Function	Automated abdominal aortic diameter quantification on contrast and non-contrast CT scans for aneurysm detection and follow-up.	AI-powered ECG analysis to detect hidden structural heart disease (heart failure, valve disease, pulmonary hypertension).

Videos

Demos, reviews, and walkthroughs featuring Bunkerhill Abdominal Aortic Quantification (AAQ) and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

Bunkerhill AAQ integrates with the Carebricks platform to automate follow-up workflows and seamlessly integrates with EHRs, turning routine CT imaging into an opportunistic screening for silent aneurysms without disrupting radiologist workflow. EchoNext is available through the OpenEvidence clinical decision support platform and analyzes standard ECGs to detect structural heart disease, fitting into existing cardiology, family medicine, hospital medicine, and internal medicine workflows.

What is the accuracy and sensitivity of each tool in detecting relevant conditions?

Bunkerhill AAQ automatically quantifies abdominal aortic diameter on contrast and non-contrast CT scans, flagging patients above configurable thresholds for vascular evaluation. EchoNext has demonstrated high accuracy, achieving an AUROC of 85% in internal tests and 78-80% in external validation, and in a study, showed higher accuracy (77%) compared to cardiologists at baseline (64%) for detecting structural heart disease.

What is the learning curve for physicians and support staff using these AI tools?

Bunkerhill AAQ is designed to assist trained medical specialists by providing maximum axial abdominal aortic diameter measurements, with results intended to be supportive rather than diagnostic and subject to review by a qualified interpreting physician. EchoNext analyzes standard 12-lead ECGs, a familiar diagnostic tool, to identify patients who should be evaluated for structural heart disease, potentially requiring a learning curve around interpreting the AI-generated risk scores and integrating them into patient management.

What kind of customer support and resources are available for implementation and ongoing use?

For Bunkerhill AAQ, interested users are directed to contact the Bunkerhill Team for workflow details and implementation. EchoNext is available through Pathway Labs, which offers tiered pricing plans that may include advanced automations and custom enhancements and integrations, suggesting varying levels of support based on the chosen plan.

Beyond HIPAA, what security measures are in place to protect patient data?

Bunkerhill AAQ utilizes AWS for its cloud infrastructure, implying the security measures inherent to that platform. EchoNext was developed using a de-identified collection of over one million ECG-echocardiogram pairs, and a de-identified dataset of 100,000 ECGs is available to promote transparency and reproducibility in research.

Are there audit-trail features to track how the AI recommendations are used and acted upon?

Bunkerhill AAQ's workflows can be configured to check for existing aneurysm surveillance, notify the responsible clinician, and schedule evaluations, with the option for manual approval before outreach, suggesting a level of traceability in actions taken. While not explicitly detailed, the integration of EchoNext into a clinical decision support platform like OpenEvidence would typically include features for tracking recommendations and physician interactions.

What clinical context or patient populations are these tools best suited for, and are there any limitations?

Bunkerhill AAQ is indicated for adults aged 22 and older for analyzing CT exams (with or without contrast) that include the L1-L5 region of the abdominal aorta, assisting in early aneurysm detection and surveillance, but is not intended for post-operative aortas. EchoNext is designed for broad access, from major hospitals to community practices, and detects hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, from standard ECGs, making it suitable for widespread screening.